Special Session

Panel 04 - (INTERACTIVE) Radiopharmaceuticals in Precision Medicine

9/15/2019
4:45 PM - 6:00 PM
Location: Room W184

Session Type: Panel
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.5 MDCB Credits

Radiopharmaceuticals have been considered appealing therapy since 131I was introduced to treat thyroid cancer. Findings in radiobiology and radiochemistry have brought new-age radiopharmaceuticals to the front edge of clinical research. The National Cancer Institute (NCI) has leveraged partnerships between its Cancer Therapy Evaluation Program and its Radiation Research Program to identify practice changing discoveries in radiopharmaceutical medicine that pulls together radiation oncologist and nuclear medicine investigators to design novel radiopharmaceutical phase I and II monotherapy or combination trials. This Presidential Symposium would discuss a modern approach to the clinical development of radiopharmaceuticals in the era of personalized medicine.

Learning Objectives:

Presentations:

Jeffrey Buchsbaum, MD, PhD, AM, FASTRO

NCI

Disclosure:
Employment
National Cancer Institute

Presentation(s):

Send Email for Jeffrey Buchsbaum


Assets

Panel 04 - (INTERACTIVE) Radiopharmaceuticals in Precision Medicine



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 04 - (INTERACTIVE) Radiopharmaceuticals in Precision Medicine